BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 38504328)

  • 1. Hereditary breast and ovarian cancer: from genes to molecular targeted therapies.
    Ponti G; De Angelis C; Ponti R; Pongetti L; Losi L; Sticchi A; Tomasi A; Ozben T
    Crit Rev Clin Lab Sci; 2023 Dec; 60(8):640-650. PubMed ID: 37455374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EMQN best practice guidelines for genetic testing in hereditary breast and ovarian cancer.
    McDevitt T; Durkie M; Arnold N; Burghel GJ; Butler S; Claes KBM; Logan P; Robinson R; Sheils K; Wolstenholme N; Hanson H; Turnbull C; Hume S
    Eur J Hum Genet; 2024 May; 32(5):479-488. PubMed ID: 38443545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted sequencing for hereditary breast and ovarian cancer in BRCA1/2-negative families reveals complex genetic architecture and phenocopies.
    Plowman JN; Matoy EJ; Uppala LV; Draves SB; Watson CJ; Sefranek BA; Stacey ML; Anderson SP; Belshan MA; Blue EE; Huff CD; Fu Y; Stessman HAF
    HGG Adv; 2024 May; 5(3):100306. PubMed ID: 38734904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tracking the dissemination of a culturally targeted brochure to promote awareness of hereditary breast and ovarian cancer among Black women.
    Scherr CL; Bomboka L; Nelson A; Pal T; Vadaparampil ST
    Patient Educ Couns; 2017 May; 100(5):805-811. PubMed ID: 27866793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1/2 variants of unknown significance in hereditary breast and ovarian cancer (HBOC) syndrome: Looking for the hidden meaning.
    Fanale D; Pivetti A; Cancelliere D; Spera A; Bono M; Fiorino A; Pedone E; Barraco N; Brando C; Perez A; Guarneri MF; Russo TDB; Vieni S; Guarneri G; Russo A; Bazan V
    Crit Rev Oncol Hematol; 2022 Apr; 172():103626. PubMed ID: 35150867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review of the molecular basis of hereditary breast and ovarian cancer syndrome in Brazil: the current scenario.
    de Freitas Ribeiro AA; Junior NMC; Dos Santos LL
    Eur J Med Res; 2024 Mar; 29(1):187. PubMed ID: 38504328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation screening of TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and ovarian cancer (HBOC) in Brazil.
    Cipriano NM; de Brito AM; de Oliveira ES; de Faria FC; Lemos S; Rodrigues AN; de Oliveira Lopes D; Dos Santos LL
    Breast Cancer; 2019 May; 26(3):397-405. PubMed ID: 30535581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry.
    Fernandes GC; Michelli RA; Galvão HC; Paula AE; Pereira R; Andrade CE; Felicio PS; Souza CP; Mendes DR; Volc S; Berardinelli GN; Grasel RS; Sabato CS; Viana DV; Mauad EC; Scapulatempo-Neto C; Arun B; Reis RM; Palmero EI
    Oncotarget; 2016 Dec; 7(49):80465-80481. PubMed ID: 27741520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of hereditary breast and ovarian cancer syndrome and sporadic ovarian cancer in ovarian cancer BRCA mutations].
    Duan RR; Sun LX; Zhao HW
    Zhonghua Fu Chan Ke Za Zhi; 2021 Nov; 56(11):788-795. PubMed ID: 34823292
    [No Abstract]   [Full Text] [Related]  

  • 11. Hereditary breast and ovarian cancer: assessment of point mutations and copy number variations in Brazilian patients.
    Silva FC; Lisboa BC; Figueiredo MC; Torrezan GT; Santos EM; Krepischi AC; Rossi BM; Achatz MI; Carraro DM
    BMC Med Genet; 2014 May; 15():55. PubMed ID: 24884479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA1 and BRCA2 germline mutation analysis from a cohort of 1267 patients at high risk for breast cancer in Brazil.
    Mazzonetto P; Milanezi F; D'Andrea M; Martins S; Monfredini PM; Dos Santos Silva J; Perrone E; Villela D; Schnabel B; Nakano V; Palmero EI; Braggio E; Cavalcanti TL; Guida G; Migliavacca MP; Scapulatempo-Neto C; Zalcberg I
    Breast Cancer Res Treat; 2023 May; 199(1):127-136. PubMed ID: 36881271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Familial history and prevalence of BRCA1, BRCA2 and TP53 pathogenic variants in HBOC Brazilian patients from a public healthcare service.
    Matta BP; Gomes R; Mattos D; Olicio R; Nascimento CM; Ferreira GM; Brant AC; Boroni M; Furtado C; Lima V; Moreira MÂM; Dos Santos ACE
    Sci Rep; 2022 Nov; 12(1):18629. PubMed ID: 36329109
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    da Silva PFF; Goveia RM; Teixeira TB; Gamba BF; de Lima AP; Rogatto SR; Silveira-Lacerda EP
    Biomolecules; 2022 Apr; 12(5):. PubMed ID: 35625568
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.